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Airway inﬂammatory processes are pivotal as the pathological features of bronchial
asthma. Standard therapy with inhaled corticosteroids markedly suppresses such
inﬂammatory changes, resulting in clinical beneﬁcial effects. However, it is now clear
that several histological changes including goblet cell hyperplasia, subepithelial collagen
deposits, increased capillary networks and smooth muscle hypertrophy can occur as a
chronic consequence of this airway disorder even when asthma is treated with inhaled or
oral steroids. These pathologic changes, the so-called remodeling, play an important role
in increased airway obstruction, increased clinical severity and difﬁculty in controlling
asthma, and eventually in the development of irreversible respiratory failure. Targeting
these remodeling changes may become a new speciﬁc therapeutic strategy for controlling
asthma.
& 2008 Elsevier Ltd. All rights reserved.Educational aims: To discuss histological evidence of small airway involve-
ment in asthma. To discuss clinical signiﬁcance of small airway remodeling
in asthma. To discuss potential tools for evaluating small airway
involvement in patients with asthma. To discuss the strengths and limitations of ultraﬁne
particle inhaled corticosteroids and systemic anti-inﬂam-
matory agents in asthma control.Elsevier Ltd. All rights reserved.
kyo-u.ac.jpIntroduction
Asthma is characterized by allergic inﬂammatory responses
associated with airway hyper-responsiveness, and is increas-
ing in prevalence and sociomedical burden in many
countries.1 Both clinical and experimental studies suggest
that eosinophils and Tcells play a key role in the induction of
airway inﬂammation and mucosal injury, which closely links
to non-speciﬁc airway hyper-responsiveness in asthma.2
Inhaled corticosteroids markedly suppress the airway hyper-
responsiveness and asthma symptoms along with decreased
eosinophil inﬁltration in the airways. More targeted types of
anti-inﬂammatory therapy such as anti-IL-5 antibody, how-
ever, have failed to show clinical improvement, despite
apparent decrease in eosinophils in the peripheral blood,
and hence posed some doubt about the critical role of this
inﬂammatory cell.3,4 It is now believed that asthma is a
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Figure 1 Involvement in large and small airways in asthma.
There exist extensive changes with so-called remodeling as well
as cell inﬁltration throughout the airways and lung parenchyma.
H. Takizawa70heterogeneous and complex airway disease that involves
both inﬂammatory and ‘‘non-inﬂammatory’’ processes.5,6
Airway structural change, the so-called ‘‘remodeling’’,
generally includes subepithelial ﬁbrosis, goblet cell hyper-
plasia, smooth muscle cells hypertrophy/hyperplasia and
microvascular changes (Figure 1).
Most of the previous reports regarding the allergic
inﬂammatory processes in asthma have been focused on
the large airways.7,8 Pathological as well as physiological
ﬁndings reported during the past few years, however,
suggest that the inﬂammatory processes involve not only
the large airways but also the smaller peripheral airways and
the lung parenchyma.9,10 In fact, the small peripheral
airways, those that are less than 2mm in diameter,11 are
recognized as a predominant site of airﬂow obstruction in
asthma.12,13 The inﬂammation in these more distal airways
has been described as more severe than large airway
inﬂammation associated with the remodeling processes.
Therefore, the peripheral airways should be considered a
prime target in therapeutic strategies for treatment of
asthma.Are small airways involved in asthma?
Considerable information about the existence of small
airway involvement in asthma has ﬁrst come from post-
mortem studies. Haley et al.14 performed a morphometric
analysis of postmortem lung specimens from patients who
succumbed to asthma. They found that the inﬂammatory
processes in distal airways appeared to be qualitatively
different from that in large airways with different distribu-
tions of cellular inﬁltrates within the walls of large and small
airways. In large airways with cartilaginous layers, relatively
more T cells and eosinophils were found in the inner region
of the airway wall (between basement membrane and
smooth muscle), compared with the outer region (between
smooth muscle and alveolar attachments). In the small
airways, however, the pattern was reversed, with CD45+ T
cells and eosinophils more abundant in the outer region.
Faul et al.15 studied inﬂammatory changes among patients
with fatal asthma with sudden death. Large numbers of T
cells and activated eosinophils were found in both proximal
and distal lung tissue. In contrast to individuals with stable
asthma, larger numbers of CD8+ T cells were found in those
with fatal asthma.
Surgically obtained lung specimens from thoracic surgery
on people with and without clinically deﬁned asthma allow
us to study larger samples than the specimens obtained
during bronchoscopic procedures. Using these larger sam-
ples, Hamid et al.16 were able to evaluate the inﬂammatoryprocess throughout the entire length of the airways. They
showed that increased numbers of T cells (CD3+), total
eosinophils (major basic protein positive) and activated
eosinophils (EG2 positive) were found in both the small
(o2mm internal diameter) and the large (42mm internal
diameter) airways of sample taken from people with asthma
compared to those without asthma. When comparing the
large and small airways in those with asthma, there were an
increased number of activated eosinophils (EG2 positive) in
small airways, suggesting that a similar but more severe
inﬂammatory process is present in the peripheral airways.
The inﬂammatory processes in the distal airways of
patients with asthma have also been studied by using
bronchoscopic techniques. Inﬂammatory inﬁltrates were
observed in the airways of both untreated and patients
receiving intensive steroid treatment, but with lesser
inﬂammation in patients with mild-to-moderate asthma.17
Evidence of distal lung inﬂammation was also reported by
Vignola et al.18 who compared several markers of inﬂamma-
tion in mucosal biopsy specimens and BAL ﬂuid from healthy
control subjects, patients with intermittent asthma, and
patients with mild-to-moderate persistent asthma. They
found that alveolar macrophage activation was signiﬁcantly
increased in patients with asthma compared with control
patients.
Kraft et al.19 studied biopsy samples from distal and
proximal lung tissue, and found that the inﬂammatory
changes that accompanied nocturnal asthma were more
prominent in the alveolar tissue area and the number of
inﬂammatory cells, especially eosinophils and macrophages,
increased at night in the alveolar tissue area of patients with
nocturnal asthma, whereas the number of inﬂammatory
cells found in the proximal airways was similar in patients
with asthma who did or did not experience nocturnal
worsening. Speciﬁcally, they further found that the pre-
sence and extent of alveolar tissue eosinophils were
correlated with nighttime decline in lung function, espe-
cially the nighttime decline in FEV1. Taken together, this
information shows that small airway involvement plays an
important role in determining clinical features and severity
of asthma.Airway remodeling in small airways of asthma:
pathological evidence
Asthma-related airway remodeling has been found to occur
in both large small airways. From autopsy studies, Carroll
et al.20 found thickening of the inner wall of distal airways in
individuals who died as a result of asthma as well as in
people with asthma who died of nonrespiratory causes
compared with airway measurements in nonasthmatic
control subjects. The increased smooth muscle mass found
in those with asthma suggests a mechanism for heightened
response to broncho-constricting stimuli. Interestingly, the
structural changes implicated in airway hyper-responsive-
ness were predominantly found in the distal airways of
nonfatal asthma cases but were also found in both large and
small airways in fatal asthma cases. These structural
changes were not focal in their distribution but
were observed throughout the distal lung.21 In specimens
from individuals who died of asthma,22 the adventitial,
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Remodeling in small airways of asthma 71submucosal and muscle areas of the distal airways were
greater than those measured in patients with chronic
obstructive pulmonary disease (COPD) and control subjects.
The smooth muscle layer in patients with asthma was 2 to 3
times thicker than that in control subjects and COPD, and
was associated with disease severity. Muscle thickness was,
in general, greater in patients with fatal asthma compared
with those with nonfatal asthma.
Autopsy studies strongly support the existence of a degree
of small airway remodeling in severe and fatal asthma, but
did not provide clear evidence of whether or how often such
structural changes were found in milder, well-controlled
asthma. Recently, evidence of remodeling in peripheral
airways of patients with mild-to-moderate asthma has been
demonstrated by Bergeron et al.23 Transbronchial and
endobronchial biopsies were obtained from 12 patients with
mild-to-moderate asthma before and after a 6-week course
of small particle hydroﬂuoroalkane (HFA)-inhaled corticos-
teroid. Total collagen occupied 37.7% of the wall area of
peripheral airways, compared with 54.5% of the wall area of
central airways (P ¼.04). After inhaled corticosteroids
therapy, there was no signiﬁcant difference in central vs.
peripheral airways for collagen III or a-smooth muscle actin
immunoreactivity and in the number of TGF-b+ cells in the
submucosa. The only signiﬁcant effect of HFA-ﬂunisolide was
a decrease in a-smooth muscle actin area in peripheral
airways that correlated with the percentage increase in
forced expiratory ﬂow at 25–75% of vital capacity. The
researchers concluded that there is a considerable degree of
airway remodeling in peripheral airways in patients with
even mild asthma and that inhaled corticosteroid do not
modulate collagen deposition and TGF-b expression. How-
ever, the treatment is associated with a signiﬁcant decrease
in the expression of a-smooth muscle actin in peripheral
airways, which correlated with the improvement in periph-
eral airway function.
Airway remodeling in the peripheral airways of
asthma: clinical implications
Physiologic consequences of small airway
involvement in asthma
Since the volume and surface area of the lungs increases
with increasing airway generations, the contribution of
peripheral resistance to the total lung resistance was
originally believed to be minimal. Ohrui et al.24 demon-
strated that there was a dose-dependent increase in both
central and peripheral airway resistance in response to
inhaled methacholine in patients with asymptomatic asthma
using a catheter-tipped micromanometer wedged into the
lower lobe of the bronchus in order to partition central and
peripheral airway resistance. Wagner et al.25 used the
wedged bronchoscopic technique to measure airway resis-
tance in the peripheral lung of patients with asymptomatic
asthma who had near-normal spirometric values. Patients
with asthma had signiﬁcantly increased peripheral airway
resistance compared with control subjects; there was more
than a 7-fold increase in peripheral lung resistance in the
asthma group. In addition, computational analyses based on
quantitative histology26 have shown the peripheral airwaysto account for the majority of airway hyper-responsiveness
among asthmatic persons. Noninvasive methodologies for
separating airway and parenchymal mechanics have been
developed using the low-frequency forced oscillation tech-
nique in humans.27 Hall et al.28 showed the contribution of
the small airways to the total lung resistance by this
technique. These observations strongly suggest that con-
tribution of the small airways to the total lung resistance has
thus far been grossly underestimated.Pathology–physiology correlations
Numerous studies have attempted to correlate clinical
measures of standard lung function with the presence and
degree of distal airway involvement. Those study suggest
that it is likely that small airway involvement contributes to
hyper-responsiveness by amplifying the effect of even slight
amounts of muscle shortening or contraction. For example,
the amount of airway smooth muscle shortening or contrac-
tion required for occluding an airway lumen is shown to be
less in asthmatic than nonasthmatic airways.29 Wagner
et al.30 examined the hyper-responsiveness in small airways
by measuring changes in peripheral resistance after a
histamine challenge by using a wedged bronchoscopic
technique. Peripheral resistance doubled at lower average
concentrations of histamine in patients with asthma
compared with healthy control subjects, indicating an
increased sensitivity to the provoking agent. Loss of lung
elasticity is an overlooked, yet potentially signiﬁcant, factor
in the loss of lung function in asthma. Although the
mechanism is unclear, the loss of elasticity is likely to
reﬂect distal airway abnormalities, especially at the
alveolar–lung parenchymal interface.31
Taken together, evidence from histologic as well as
physiologic studies indicates that distal airways of indivi-
duals with asthma undergo pronounced and, perhaps,
permanent structural changes along with long-standing
inﬂammation that appears to affect coarse measures of
lung performance. Structural changes, with wall thickening
being the most pronounced, are likely to contribute to
hyper-responsiveness. These structural changes in distal
airways were observed even in patients receiving corticos-
teroid therapy, suggesting that this therapy did not
completely control distal airway inﬂammation.Assessment of small airway changes in asthma
As described, the small airways were once called the ‘‘silent
zone of the lung’’. It is not easy to assess the disease
processes of this area in clinical practice. While classic
spirometry and ﬂow-volume curves are routinely evaluated
in daily practice, application of parameters of small
airways, such as V25 or V50/V25, has been limited because
of their lack of reproducibility. Low-frequency forced
oscillation technique might be an alternative.27,28 In
addition, several research methods including CT, ultrathin
bronchoscopy or microsampling have been proposed for
evaluation of small airways in asthma. To date none of these




High-resolution CT (HRCT) studies can reveal anatomic
details of the lung only as small as 200–300 mm, correspond-
ing to wall thickness in airways 2mm in diameter or larger.32
At present, therefore, this method is inadequate for
directly visualizing small airways. Alternatively, HRCT has
proved to be useful to detect functional changes in the
small airways by indirectly monitoring air trapping at
distal sites.33 Air trapped in the mid-zone airways at residual
lung volume after methacholine challenge can be
indirectly detected by HRCT, appearing as regions of
decreased signal attenuation. Patients with moderate
asthma exhibit an aberrant ‘‘mosaic’’ pattern of pulmonary
perfusion, which is correlated with small airway obstruction
as indicated by air trapping on HRCT and may therefore
be useful for the evaluation of therapeutic effects (see
below).
Other potentially available tools
As described above, application of ﬁbroptic bronchoscopy in
asthma has greatly facilitated understanding of the airway
changes by obtaining biopsy samples from the large airways
in patients with asthma. We successfully harvested living
epithelial cells by brushing the small airway mucosa under
direct vision by using a newly developed ultrathin bronch-
oﬁberscope BF-2.8 T (the outer diameter: 2.7mm with a
biopsy channel of 0.8mm in diameter).34 It is well known
that airway epithelial cells are potent sources of proﬁbrotic
growth factors and inﬂammatory cytokines. We recruited
healthy non-smokers (n ¼ 8) and mild asthmatics (n ¼ 8),
and recovered peripheral airway epithelial cells after
informed consent. Among the factors studied, TGF-b-1
mRNA levels signiﬁcantly increased and showed a signiﬁcant
inverse correlation with percent V25 and V50/V25 after
bronchodilator treatment. These ﬁndings may highlight the
role of airway epithelium-derived TGF-b-1 in the irreversible
small airway obstruction found in chronic asthma, fre-
quently observed as airway remodeling (manuscript in
preparation).
Small airways as a therapeutic target in asthma
Although inhaled corticosteroids reduce airway inﬂamma-
tion in patients with asthma,1 prolonged courses of inhaled
steroids do not normalize hyper-responsiveness. Further-
more, it was demonstrated in deposition studies that most
of the currently used inhaled corticosteroids are predomi-
nantly deposited in the large airways and not in the lung
periphery. Therefore, therapeutic actions of inhaled corti-
costeroids at sites of small airway involvement must be
improved.
Metered-dose inhaler (MDI) corticosteroids
Aerosol particle size is a key element in determining lung
deposition and the regional distribution of inhaled medica-
tion within the lung. In general, smaller aerosol particles are
more likely to be deposited in the lung. The fraction of
particles emitted by a pressurized MDI is closely related tothe percent of deposition in the lung; aerosol particles with
a mass median of approximately 4.7mm are respirable. In
the lung, the smaller and less dense the particle, the more
likely it is to reach the distal regions. However, particles
between 0.6 and 0.3 mmmass median aerodynamic diameter
are often exhaled.12
Deposition studies by scintigraphic techniques with
technetium Tc 99m-radiolabeled HFA-beclomethasone
(BDP) (mean diameter:1.1 mm) and classical chloroﬂuoro-
carbon (CFC)-BDP (mean diameter:3.5 mm) clearly showed
that BDP in HFA showed an increased deposition compared
with BDP with CFC (55–60% vs. 4–7%).35 In addition to
increasing lung deposition, the reduction in oropharyngeal
deposition with HFA formulation can minimize local side
effects.
Goldin et al.36 used HRCT and regional air trapping to
compare the efﬁcacy of HFA– and CFC–corticosteroid
formulations in corticosteroid-naive patients with mild-to-
moderate asthma. Pretreatment functional CT studies
before and after a methacholine challenge were performed
at baseline and after 4 weeks of treatment. Post-treatment
scanning indicated signiﬁcant improvement in air trapping
for both groups. However, after challenge with equal
constrictor stimuli, smaller increases in air trapping were
observed for subjects treated with the HFA formulation.
Corren et al.37 showed comparable efﬁcacy between
ﬂunisolide HFA at one-third the dose of its CFC counterpart.
However, trends favored ﬂunisolide HFA on several para-
meters, including 40.4% fewer asthma exacerbations.
Similar efﬁcacy at lower doses was reported for HFA-BDP
compared with CFC-BDP in a 6-week study by Busse et al.38
Ciclesonide is delivered as a small-particle inhaled corticos-
teroid with HFA and improves lung function and airway
hyper-responsiveness. Cohen et al.39 assessed whether
ciclesonide can speciﬁcally improve small airway function
in asthma. Sixteen mild-to-moderate asthma patients (7
males, median age 39 (range 19–56) years, FEV1% predicted
89% (range 62–120)) were randomized to a 5-week treat-
ment with placebo or 320 mg ciclesonide once daily. Both CT
measurements of expiratory lung volume after methacholine
challenge and alveolar eNO decreased signiﬁcantly more
with ciclesonide than with placebo. Ciclesonide did not
signiﬁcantly improve other small airways parameters such as
FEF25–75%, percentage fall in FVC at PC20adenosine-’5-
monophosphate (AMP) and at PC20methacholine. This
recent report suggests that ciclesonide in HFA exerts anti-
inﬂammatory effects on small airways. However, longer-
term efﬁcacy especially on small airway remodeling remains
to be studied.Dry powder inhalers
Dry powder inhalers (DPIs) represent another alternative to
HFA-pMDIs. Data on regional lung deposition and distal lung
access by DPI-delivered corticosteroids are limited. It has
been demonstrated that deposition with DPIs is dependent
on inspiratory ﬂow rates (IFRs), with faster ﬂow rates
seeming to increase lung deposition. For example, scinti-
graphic imaging of budesonide delivered by DPI in healthy
volunteers showed an overall pulmonary deposition of 14.8%
and 27.7% at slower and faster IFRs, respectively.40
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Figure 2 Therapeutic strategies for the treatment of small
airways with asthma. Fine particle-corticosteroids in HFA
formulations show increased deposition in small airways and
are expected to inhibit inﬂammatory changes in these areas,
but anti-remodeling effects remain to be clariﬁed. Systemic
anti-asthma drugs such as leukotriene antagonists would
become alternative approaches.
Remodeling in small airways of asthma 73Oral agents: an alternative route to the distal lung?
Oral agents would be other candidates that have access to
this area of the lung through the circulation (Figure 2). The
leukotriene receptor antagonists are oral anti-inﬂammatory
agents with bronchodilating activity.41 They are efﬁcacious
and safe for the treatment of asthma in adults and
children.1,41 In animal models of asthma, these agents are
reported to prevent airway remodeling processes.42 There is
one clinical study which supports potential beneﬁt of this
class of agent.43 However, speciﬁc studies are needed to
deﬁne the potential action of anti-leukotrienes on distal
airway inﬂammation and remodeling. Treatment of asthma
as a systemic disease could become a new paradigm, and
systemic anti-inﬂammatory and anti-remodeling therapy
might be necessary for the complete control of this
disease.44,45
Practice points: importance of small airway
involvement in asthma Difﬁcult to detect: limitation of techniques, the so-called
Silent Zone Easy to be targeted: noxious agents such as tobacco, air
pollutants, viruses, etc. Difﬁcult to defend: lack of effective defense
 Disturbed lung function: remodeling causing irreversible
obstructive changes
 Difﬁcult to treat: needs strategy to drug treatment
Conclusion
There is accumulating evidence to suggest that small airway
involvement plays a crucial role in the disease processes in
asthma. It is anticipated that poorly controlled inﬂammation
in small airways may contribute to accelerated decline in
lung function and airway remodeling. The application of
HRCT appears to allow indirect assessment of the morpho-logical changes (resulting from air trapping and regional
hyperinﬂation) in the small airways, still remains research
tools. Less-invasive and concise techniques would be
necessary for clinical evaluation of the disease at this site.
Remodeling processes in this site would become important
new therapeutic target in asthma.
CME Section
This article has been accredited for CME learning by the
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administrative charge).Educational questions
Answer true or false to the following statements:1. Asthma is an inﬂammatory disease that affects only large
airways.2. Airway inﬂammations show different patterns in large
and small airways.3. Airway remodeling is associated with increased smooth
muscle thickness in both large and small airways.4. Treatment with inhaled corticosteroids clear all ﬁndings
of airway remodeling in patients with milder asthma.5. In asthma airway resistance is not inﬂuenced by the
smaller more peripheral airways.6. HRCT scans can directly assess small airway remodeling.
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